Latest Articles
BioGrad opens Europe’s first private research tissue bank as part of a £25m investment into women’s health - Invest Liverpool
BioGrad opens Europe’s first private research tissue bank as part of a £25m investment into women’s health Invest Liverpool
Published: Jan. 21, 2025, 9:51 a.m.
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? - Medscape
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? Medscape
Published: Jan. 21, 2025, 9:45 a.m.
EC approves GSK’s Jemperli-chemo combo for endometrial cancer - Pharmaceutical Technology
EC approves GSK’s Jemperli-chemo combo for endometrial cancer Pharmaceutical Technology
Published: Jan. 21, 2025, 9:35 a.m.
Woman Details Having Dramatic Surgery at 23 Years Old After Symptoms 'So Severe' She Almost Didn't Graduate College (Exclusive) - PEOPLE
Woman Details Having Dramatic Surgery at 23 Years Old After Symptoms 'So Severe' She Almost Didn't Graduate College (Exclusive) PEOPLE
Published: Jan. 21, 2025, 9:30 a.m.
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer - Medical Dialogues
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer Medical Dialogues
Published: Jan. 21, 2025, 8 a.m.
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer - Indian Pharma Post
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer Indian Pharma Post
Published: Jan. 21, 2025, 4:36 a.m.
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - ABN Newswire
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR ABN Newswire
Published: Jan. 21, 2025, 12:38 a.m.
17 cancer symptoms you should never ignore as record number of people living with disease - Surrey Live
17 cancer symptoms you should never ignore as record number of people living with disease Surrey Live
Published: Jan. 21, 2025, 12:01 a.m.
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer - OncLive
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer OncLive
Published: Jan. 20, 2025, 9:34 p.m.
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer - Cancer Network
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer Cancer Network
Published: Jan. 20, 2025, 5:08 p.m.
Link copied to clipboard!